NASDAQ:CLGN

Collplant Biotechnologies Stock Insider Trading

Healthcare > Biotechnology

Buy CLGN

*Your capital is at risk

$0.352

+0.0142 (+4.20%)

At Close: Jun 23, 2026

CollPlant Biotechnologies Stock Insider Power

Based on the 34 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 479.4K and sold 0 CLGN shares in the last 34 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 34 transactions)	0
● Buy	479.4K shares
● Sell	0 shares
100% Buy Activity Moderate Positive Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 19, 2026 Buy	Restricted Share Units	Tal Yehiel Chief Executive Officer	CEO / President	0 Value: $0
Mar 19, 2026 Buy	Ordinary Shares	Tal Yehiel Chief Executive Officer	CEO / President	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Evans Hugh M Director	Director	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Evans Hugh M Director	Director	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Evans Hugh M Director	Director	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Evans Hugh M Director	Director	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Penn Elan Director	Director	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Havron Avraham Director	Director	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Bagley Bowman Vp Commercial North America	Officer	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Abelis Bar Berta Vp Legal	Officer	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Abelis Bar Berta Vp Legal	Officer	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Seror Jasmine Vp Product Development	Officer	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Bensimon Philippe Vp Regulations And Qa	Officer	0 Value: $0
Mar 18, 2026 Buy	Ordinary Shares	Bensimon Philippe Vp Regulations And Qa	Officer	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Fahimipoor Oren Vp Operations	Officer	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Rotem Eran Deputy CEO And CFO	CEO / President	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Lask Alisa Director	Director	0 Value: $0
Mar 18, 2026 Buy	Restricted Share Units	Seror Jasmine Vp Product Development	Officer	0 Value: $0
Mar 28, 2024 Buy	Options to Purchase Ordinary Shares	Abelis Bar Berta Vp Legal	Officer	20 000 Value: $150.0K
Mar 28, 2024 Buy	Options to Purchase Ordinary Shares	Fahimipoor Oren Vp Operations	Officer	50 000 Value: $375.0K
May 02, 2023 Buy	Options to Purchase Ordinary Shares	Evans Hugh M Director	Director	24 000 Value: $153.4K
May 02, 2023 Buy	Options to Purchase Ordinary Shares	Tal Yehiel Chief Executive Officer	CEO / President	100 000 Value: $639.0K
May 02, 2023 Buy	Options to Purchase Ordinary Shares	Penn Elan Director	Director	24 000 Value: $153.4K
May 02, 2023 Buy	Options to Purchase Ordinary Shares	Havron Avraham Director	Director	24 000 Value: $153.4K
May 02, 2023 Buy	Options to Purchase Ordinary Shares	Lask Alisa Director	Director	47 000 Value: $300.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT COLLPLANT BIOTECHNOLOGIES LTD.

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and...

Read Full Profile Here